Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblasti... ( BETHESDA and GAITHERSBURG Md. Jun...)

HOME >> MEDICINE >> TECHNOLOGY

Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia

Date:6/12/2008

BETHESDA and GAITHERSBURG, Md., June 12 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI) and MedImmune announced today that the first patient has started treatment in a multi-center, phase 2 trial conducted in Germany investigating BiTE(R) antibody blinatumomab (MT103/MEDI-538) in patients with adult acute lymphoblastic leukemia (ALL). Blinatumomab is a T cell engaging antibody targeting the CD19 antigen, which is only expressed on B cells. The clinical development program for blinatumomab was expanded to include ALL as an additional indication after data from an ongoing phase 1 clinical trial showed potent single-agent activity of the BiTE antibody in patients with late-stage non-Hodgkin's lymphoma (NHL). These data were presented last December at the 2007 Annual Meeting of the American Society of Hematology (ASH), and an update of this trial was presented last week at the 10th International Conference on Malignant Lymphomas (ICML) in Lugano, Switzerland.

"This phase 2 clinical trial in ALL is an important step to assess activity of blinatumomab in aggressive forms of B cell malignancies and will help to determine the full therapeutic potential of this highly specific and potent BiTE antibody in human B cell cancers," said Carsten Reinhardt, M.D., senior vice president and chief medical officer of Micromet.

ALL is a very aggressive form of B cell leukemia. Patients with ALL are initially treated with complex and highly toxic chemotherapy regimens, which may be followed by bone marrow stem cell transplantation for eligible patients. Patients who have a low number of residual tumor cells in their bone marrow after chemotherapy (also known as "minimal residual disease" or MRD) are at a very high risk of early relapse. T
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. Micromets BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkins Lymphoma
2. Micromet to Present Clinical Update for BiTE Antibody MT103/MEDI-538 at the International Conference on Malignant Lymphomas
3. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
4. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
5. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
6. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
7. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
8. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
9. Micromet Announces Changes in Management Team
10. MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13
11. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma

Post Your Comments:

(Date:5/22/2013)... May 22, 2013 Hemoglobin A1C levels ... with Type 2 diabetes, while modest improvements in ... outcomes and can lead to substantial healthcare cost ... International Society for Pharmacoeconomics and Outcomes Research (ISPOR) ... studies, sponsored by Valeritas, makers of the V-Go ...

(Date:5/22/2013)... and TORONTO , May ... (OTCBB: GNBT) today announced three presentations demonstrating the superiority ... its wholly-owned subsidiary, Antigen Express, Inc. ( www.antigenexpress.com ). ... of the American Society of Clinical Oncology (ASCO) to ... May 31 through June 4, 2013. The ...

(Date:5/22/2013)... Mass. , May 22, 2013 Flagship ... firm focused on healthcare and sustainability, today announced ... as a Senior Partner. In this role, ... to portfolio companies. In addition to ... Mr. Bancel also serves as President and Chief ...

Breaking Medicine Technology:Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 2 Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 3 Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 4 Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 5 Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 6 Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 2 Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 3 Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 4 Life Science Industry Veteran Stephane Bancel Joins Flagship Ventures 2 Life Science Industry Veteran Stephane Bancel Joins Flagship Ventures 3

[0] Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance [0] Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine [0] Life Science Industry Veteran Stephane Bancel Joins Flagship Ventures

... reduced signs and symptoms of SLE,disease at ... activity at 76 weeks-, ROCKVILLE, Md., June ... today announced the presentation of Phase 2,trial ... activity across multiple clinical,measures, was well tolerated ...

... - Neurogen,Corporation (Nasdaq: NRGN) today announced that data ... for NG2-73, the Company's,lead compound for the treatment ... SLEEP 2007 Annual Meeting of the Associated,Professional Sleep ... studies with NG2-73 in chronic insomnia patients,are currently ...

Cached Medicine Technology:Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 2 Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 3 Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 4 Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 5 Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 6 Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 7 Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 8 Neurogen Proprietary Insomnia Compound Data for Two Studies,Presented at Associated Professional Sleep Societies Annual Meeting 2 Neurogen Proprietary Insomnia Compound Data for Two Studies,Presented at Associated Professional Sleep Societies Annual Meeting 3 Neurogen Proprietary Insomnia Compound Data for Two Studies,Presented at Associated Professional Sleep Societies Annual Meeting 4 Neurogen Proprietary Insomnia Compound Data for Two Studies,Presented at Associated Professional Sleep Societies Annual Meeting 5

Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus Neurogen Proprietary Insomnia Compound Data for Two Studies,Presented at Associated Professional Sleep Societies Annual Meeting

(Date:5/22/2013)... The Muscular Dystrophy Association scored a huge ... annual Charlotte Muscle Team event held May 21 by ... with muscle disease. , "The Charlotte community really ... families,” said MDA Divisional Director Theresa Miller. “From the ... "Buddy" to make their night extra special, to the ...

(Date:5/22/2013)... Amy Norton HealthDay Reporter , , WEDNESDAY, May ... with athlete,s foot knows there is something about feet ... the first detailed "map" of the fungal groups that ... feet are the hottest neighborhood. It,s no secret ... such as bacteria, viruses and fungi, both outside and ...

(Date:5/22/2013)... People in the United States have been taking water ... much of the world, water shortages are normal and baths ... warns against taking water for granted and provides ways to ... in the United States. , Sharon Kleyne is host of ... live or by podcast on World Talk Radio, Voice America, ...

(Date:5/22/2013)... ID (PRWEB) May 22, 2013 Bodybuilding.com ... This Memorial Day (May 27, 2013) Bodybuilding.com will be donating ... of the amount. , “We are extremely grateful for ... the Armed Forces,” said Ryan DeLuca, CEO and founder of ... heroes who have sacrificed so much. Hire Heroes USA is ...

(Date:5/22/2013)... (PRWEB) May 22, 2013 Twenty student-led ... next year participating in an intensive startup accelerator designed ... products or services and create local jobs as part ... Each year the Edson initiative offers approximately 20 student ... space, mentorship and training to launch their for-profit, more-than-profit ...

[0] Charlotte Muscle Team Event Raises $300,000 in the Fight Against Muscle Disease [0] Scientists Map the Fungi on Your Feet [0] Water Advocate Sharon Kleyne Announces Water Conservation Appreciation [0] In the Spirit of Memorial Day, Bodybuilding.com is Donating a Portion of Their Sales to Hire Heroes [0] ASU Announces Edson Student Entrepreneur Initiative’s 2013-2014 Cohort

... , , , ... diagnostic services for veterinarians and pet owners, announced today it has ... Company and ProScan Imaging, both headquartered in Cincinnati. Financial terms were ... in Vienna, Va., Raleigh, N.C. and San Francisco and is the ...

... , Paul A. Markowski to Join ACCP as ... Aug. 10 The American College of Chest Physicians announced today that ... new Executive Vice President and CEO for the international medical specialty society. ... and CEO in the society,s 75-year history. , , ...

... Conn., Aug. 10 VION PHARMACEUTICALS, INC. (OTC ... the Oncologic Drugs Advisory Committee (ODAC) Meeting at which its ... , , The ODAC reviews and ... investigational human drug products for use in the treatment of ...

... Indiana University,s Center for Health Policy and Professionalism Research ... for individuals under age 65 remains virtually the same ... involved the government would be. Many ... insurance option, such as that being proposed by President ...

... human cancer tumors, the Ras protein literally "drives cells crazy," ... Life Sciences at Tel Aviv University. Prof. Kloog was the ... against pancreatic cancer, currently in clinical trials. Now, new research ... Pharmacology shows that the drug might be able to slow ...

... The Fountain of Life Group was in Canton, Ohio this weekend ... Pro Football Hall of Fame Yearbook. Fountain of Life is excited ... support of the Hall,s flagship publication. VaNu is featured in the ... Roger Staubach. , , The Pro Football Hall ...

Cached Medicine News:Health News:AnimalScan, LLC Acquires Iams Pet Imaging, LLC 2 Health News:American College of Chest Physicians Names New CEO 2 Health News:Vion Pharmaceuticals Announces Oncologic Drugs Advisory Committee Meeting for Onrigin(TM) 2 Health News:Vion Pharmaceuticals Announces Oncologic Drugs Advisory Committee Meeting for Onrigin(TM) 3 Health News:Americans remain divided on government involvement in health insurance, IU survey shows 2 Health News:Americans remain divided on government involvement in health insurance, IU survey shows 3 Health News:Taking the needle's sting out of diabetes 2 Health News:Fountain of Life Group Debuts VaNu at the Pro Football Hall of Fame Enshrinement Weekend 2

AnimalScan, LLC Acquires Iams Pet Imaging, LLC American College of Chest Physicians Names New CEO Vion Pharmaceuticals Announces Oncologic Drugs Advisory Committee Meeting for Onrigin(TM)Americans remain divided on government involvement in health insurance, IU survey shows Taking the needle's sting out of diabetes Fountain of Life Group Debuts VaNu at the Pro Football Hall of Fame Enshrinement Weekend

... The SmartCycler System is a rapid, real-time ... prepared biological samples. By automating much of ... site individually programmable, it is the fastest, ... now on the market. The SmartCycler delivers ...

... Block and its operation software are ... of gene expression, genotyping, counting bacterial/viral ... microarray results. Exicycler is capable of ... such as protein-protein and protein-ligand, using ...

... easily converts any DNA Engine thermal cycler into ... with any of our user-changeable sample blocks. The ... it to keep pace with the evolving needs ... DNA Engine base units, new or existing. The ...

Mx3000P instrument, desktop computer, Mx3000P software package, user's manual, one Brilliant QPCR Reagent of your choice, and custom filter wheel with 4 filters chosen from: FAM/SYBR Green I, TET, HE...

Medicine Products:

SmartCycler® 3200 System Exicycler™ Real-time Thermal Block Chromo 4 Four-Color Real-Time System Mx3000P Real-Time PCR System (110 volt) with Desktop Computer